AzTrials
AzTrials

Pancreatic CancerPhase 1/2NCT05419479

Switch Maintenance in Pancreatic

A Phase 1/2 study testing ZIMBERELIMAB, DOMVANALIMAB and APX005M in people with Pancreatic Cancer and Adenocarcinoma of the Pancreas, run by James Cleary, MD, PhD at 1 site in United States.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
ZIMBERELIMAB, DOMVANALIMAB and APX005M
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteUnited States
Study dates
30 Nov 2022to 17 May 2032
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants must have histologically confirmed pancreatic cancer (adenocarcinoma, squamous, or adenosquamous histologies) that is metastatic and for which standard curative or palliative measures do not exist or are no longer effective. Locally advanced patients are not eligible.
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
  • Participants must have received 8-12 cycles (4-6 months) of first-line FOLFIRINOX or modified FOLFIRINOX with stable disease or better.
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of domvanalimab + zimberelimab + APX005M in participants <18 years of age, children are excluded from this study.
  • ECOG performance status ≤1
  • Participants must have adequate organ and marrow function as defined below:
Show all 31Show fewer
  • leukocytes ≥3,000/mcL
  • absolute neutrophil count ≥1,500/mcL
  • platelets ≥100,000/mcL
  • total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except in patients with documented Gilbert's syndrome, who must have a total bilirubin ≤ 3 x ULN
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 x institution's upper limit of normal (ULN) for patients with no concurrent liver metastases, OR ≤ 5.0 x institution's ULN for patients with concurrent liver metastases creatinine OR glomerular filtration rate (GFR) creatinine ≤ 2 x ULN OR GFR measured by calculated creatinine clearance (CrCl) > 45 mL/min. CrCl can be calculated using the Cockroft-Gault method.
  • Hemoglobin (Hgb) >9.0 g/dL
  • Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. If a participant has brain or meningeal metastases, the participant must meet the following criteria:
  • Have no evidence of progression by neurologic symptoms or sign for at least 4 weeks prior to the first dose.
  • Metastatic brain lesions do not require immediate intervention.
  • Carcinomatous meningitis is excluded regardless of clinical stability.
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
  • Participants must be willing to undergo a pre-treatment fresh tumor biopsy.
  • Participants must be willing to undergo an on-treatment tumor biopsy (if medically feasible).
  • Participants must have archival tissue available for analysis, which will be used for correlative studies if a pretreatment biopsy reveals necrotic tissue.
  • The effects of domvanalimab, zimberelimab, and APX005M on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (See Section 5.6) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of domvanalimab, zimberelimab, or APX005M administration.
  • Women of childbearing potential (WOCBP), defined as not surgically sterilized and between menarche and 1-year post menopause, must have a negative serum pregnancy test within 7 days prior to the first dose of investigational therapies and a negative urine (or serum) pregnancy test within 3 days prior to the first dose of investigational therapies.
  • WOCBP must agree to use highly effective methods of contraception from the time of consent, through the duration of study treatment, and 5 months after the last dose of investigational therapies.
  • Male participants with WOCBP sexual partners must agree to use highly effective methods of contraception, and to refrain from donating sperm from the time of consent through the duration of study treatment and 7 months after the last dose of investigational therapies. Contraceptive requirements may be extended depending on local regulatory requirements.
  • Female participants must not be breast feeding and must not breast-feed a baby while on treatment and for up to 7 months after the last dose of investigational therapies.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Willing and able to comply with the requirements and restrictions in this protocol.
  • Eligibility Criteria for Stage 2 (Crossover Stage)
  • Patients must meet all of the criteria used for Stage 1.
  • Patients allocated to the control arm (Arm B) during Stage 1 have the ability to initiate Stage 2 treatment within 4 weeks after experiencing disease progression per RECIST v1.1 while receiving control treatment
  • Availability of a tumor specimen from on-treatment biopsy during Expansion Phase. If this is not available, willingness to undergo biopsy prior to initiation of Crossover Phase.

Who cannot join

  • Patients who have evidence of disease progression on FOLFIRINOX.
  • Participants who have had cytotoxic chemotherapy, radiotherapy, within 2 weeks prior to the first dose of study medication or those who have not recovered to ≤ CTCAE Grade 1 or baseline from adverse events due to agents administered more than 2 weeks earlier. Exceptions include alopecia of any grade and Grade ≤ 2 peripheral neuropathy.
  • Participants who have received any other investigational agents for pancreatic cancer.
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, or allergic reactions attributed to compounds of similar chemical or biologic composition to domvanalimab, zimberelimab, APX005M, or other agents used in study.
  • Prior treatment with any of the protocol-specified study treatments, with the exception of chemotherapy.
  • Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies (including anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-TIGIT, and CD40 agonist therapeutic antibodies)
Show all 25Show fewer
  • Patients with endocrine or acinar pancreatic carcinoma are not eligible for the study.
  • Known dihydropyrimidine dehydrogenase deficiency.
  • Patients who are enrolling after achieving at least stable disease on FOLFIRINOX are not eligible if they have a germline BRCA1 or BRCA2 mutation(s).
  • Participants who have undergone major surgery 28 days prior to initiating protocol therapy. Participants must have sufficiently recovered from adverse events caused by the procedure as judged by the treating investigator. Placement of central venous access catheter (e.g., port or similar) is not considered a major surgical procedure.
  • Participants must not have a history of human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV), except for the following:
  • Participants with anti-HepB core antibody but with undetectable HepB virus deoxyribonucleic acid (DNA) and negative for HepB surface antigen
  • Participants with resolved or treated hepatitis C virus (HCV) (i.e., HCV antibody positive but undetectable HCV RNA)
  • Participants must not have a history of primary immunodeficiency.
  • Active autoimmune disease, history of autoimmune disease, or concurrent administration of immune suppressive medications. Participants must not have a known or suspected history of an autoimmune disorder within 3 years of the first dose of investigational agent, including but not limited to: systemic lupus erythematosus, scleroderma, inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, sarcoidosis, or autoimmune hepatitis. Exceptions include participants with Type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders such as alopecia or vitiligo, not requiring systemic therapy, resolved childhood asthma/atopy, or conditions not expected to recur in the absence of an external trigger are eligible. Patients with a history of Hashimoto syndrome within 3 years of the first dose of investigational agent, which resolved to hypothyroidism alone.
  • Prior allogeneic bone marrow transplantation or solid organ transplantation.
  • Participants must not receive concurrent or prior use of an immunosuppressive agent within 14 days prior to the first dose of investigational agent. Exceptions include:
  • Systemic steroids at physiologic doses (equivalent to dose of ≤ 10 mg oral prednisone) are permitted.
  • Intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with minimal systemic absorption are permitted.
  • Patients with a condition with anticipated use of systemic steroids above the equivalent of 10 mg prednisone are excluded.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • Patients must not have received a live attenuated vaccine within 28 days before the first dose of investigational agent, and patients, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of investigational agent. Prior COVID-19 infection and/or COVID-19 vaccination is permitted.
  • Known hereditary or acquired coagulopathy (e.g., hemophilia, von Willebrand disease, cancer-associated diffuse intravascular coagulation)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of investigational therapy), clinically significant cardiovascular disease, unstable angina pectoris, cardiac arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Participants with a history of a clinically relevant second primary malignancy within the past 2 years. Exceptions include: resected basal and squamous cell carcinomas of the skin and completely resected carcinoma in situ of any type.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115

Other trials in United States

About this study

Official title: Phase Ib Open-Label, Multicenter, Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and Sotigalimab in Patients With Metastatic Pancreatic Cancer

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body.

This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells.

The names of the study drugs involved in this study are:

  • Domvanalimab (also known as AB154)
  • Zimberelimab (also known as AB122)
  • APX005M
Read the detailed description

This is an open-label, Phase 1b/2, multicenter, randomized study evaluating the safety and efficacy of 'switch maintenance' combination immunotherapy (domvanalimab) zimberelimab and APX005M versus 'continuous maintenance' in patients with metastatic pancreatic cancer following 4-6 months of FOLFIRINOX

The names of the study drugs involved in this study are:

  • Domvanalimab (also known as AB154)
  • Zimberelimab (also known as AB122)
  • APX005M

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

Participants will be randomized into one of two groups:

  • Arm A will receive domvanalimab, zimberelimab, and APX005M every two weeks through an infusion.
  • Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion

If you are in Arm B and the drugs stop working, participants may receive the drugs given in Arm A.

Participants will receive study treatment as long the disease does not worsen or there are no serious side effects for a maximum of 26 cycles (2 years) and will be followed for 12 months after the discontinue the study drugs.

It is expected that about 46 people will take part in this research study.

This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational drug or drugs and also tries to define the appropriate dose of the investigational drug(s) to use for further studies. Phase II clinical trials test the safety and effectiveness of an investigational drug or drugs to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved domvanalimab, zimberelimab, or APX005M as a treatment for any disease.

drug regimen.

Being tested
ZIMBERELIMAB, DOMVANALIMAB, APX005M, FOLFIRI
Keywords
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
Medical subject headings
Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ZIMBERELIMABDrug

    Also called AB 122

    Via IV on two days per cycle, dosage per protocol

  • DOMVANALIMABDrug

    Also called AB 154

    Via IV on two days per cycle, dosage per protocol

  • APX005MDrug

    Also called CD40

    Via IV on two days per cycle, dosage per protocol

  • FOLFIRIDrug

    every two weeks through an infusion at a dose determined by physician

Study groups in NCT05419479
Study groupRoleWhat they receive
LEAD-IN: DOSE DE-ESCALATIONExperimentalThe lead-in dose de-escalation cohort (Phase 1b) will enroll 6 patients (up to 12 patients in 2 dose levels if needed; 6 patients per DL) to receive zimberelimab, domvanalimab, and APX005M
Receives: Drug: ZIMBERELIMAB; Drug: DOMVANALIMAB; Drug: APX005M
ARM A: ZIMBERELIMAB + DOMVANALIMAB + APX005MExperimentalParticipants will be randomly assigned to one of two groups Arm A will receive domvanalimab, zimberelimab, and APX005M every two weeks through an infusion.
Receives: Drug: ZIMBERELIMAB; Drug: DOMVANALIMAB; Drug: APX005M
ARM B: FOLFIRIActive comparatorArm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion
Receives: Drug: FOLFIRI
CROSSOVER: ZIMBERELIMAB + DOMVANALIMAB + APX005MExperimentalParticipants in Arm B (control arm) who experience disease progression (as defined by RECIST v1.1) will be given the option to crossover and receive domvanalimab + zimberelimab, + APX005M in the second-line setting, provided they meet eligibility criteria
Receives: Drug: ZIMBERELIMAB; Drug: DOMVANALIMAB; Drug: APX005M

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dose-limiting toxicities-Phase 1

    Toxicity assessments will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Measured: 28 Days

Secondary outcomes (6)

  1. Objective Response Rate (ORR)

    Tumor reassessment with baseline CT scan and restaging scans will occur every 8 weeks using RECIST v1.1

    Measured: Every 8 weeks up to 38 Months

  2. Disease Control Rate

    Tumor reassessment with baseline CT scan and restaging scans will occur every 8 weeks using RECIST v1.1

    Measured: Every 8 weeks up to 38 Months

  3. Switch Maintenance-Progression Free Survival

    PFS will also be measured for post-Folfirinox (PFS2). PFS is defined as the time from registration to the Crossover Arm to the earlier of progression or death due to any cause.

    The PFS2 distribution will be calculated and plotted using the Kaplan-Meier method

    Measured: baseline up to 38 months

  4. Duration of Response (DoR)

    The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started, or death due to any cause. Participants without events reported are censored at the last disease evaluation).

    Measured: Baseline up to 38 Months

  5. Overall Survival

    Overall Survival (OS) is defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

    Measured: baseline up to 38 months

  6. Number of Participants With Treatment-Related Adverse Events

    Toxicity assessments will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Measured: Up to 38 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2022
  2. Study start30 Nov 2022
  3. Primary completion17 May 2026
  4. Study completion17 May 2032 (estimated)

Why it stopped: Efficacy concerns.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
46 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05419479
Sponsor's protocol ID
22-141
Status last verified
Feb 2026
First submitted
10 Jun 2022
Last updated
4 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing ZIMBERELIMAB, DOMVANALIMAB and APX005M in people with Pancreatic Cancer and Adenocarcinoma of the Pancreas, run by James Cleary, MD, PhD at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 31 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dose-limiting toxicities-Phase 1 (time frame: 28 Days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05419479.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in